A.BailisW

In laboratory and pre-clinical settings, PT-141 (Bremelanotide) is studied as the defining CNS melanocortin agonist for sexual behaviour neuroscience and melanocortin receptor pharmacology: MC4R pharmacology receptor binding kinetics, Gs/cAMP/PKA signalling, hypothalamic expression mapping, and MC4R-selective research design Melanocortin receptor profiling MC1R/MC3R/MC4R/MC5R binding affinity, SAR studies, and MCR subtype selectivity research Central sexual behaviour neuroscience mPOA and PVN neuronal activation, c-Fos immunoreactivity, and hypothalamic circuit mapping Dopamine system modulation mPOA dopamine release, nucleus accumbens reward integration, and monoaminergic neurotransmitter crosstalk Oxytocin circuit activation PVN oxytocin neuron stimulation and affective/bonding dimension of sexual response HSDD research models female sexual desire deficiency models, melanocortin excitatory pathway engagement, and excitation/inhibition balance Erectile dysfunction research MC4R-mediated erectile pathway, PVN-corpus cavernosum neural connectivity, and PDE5-independent erection modelling CNS vs peripheral mechanism dissection central melanocortin pathway vs nitric oxide/PDE5 axis

Clinical trials suggest GLP-1 medications are safe for diverse patient populations
Creatine is usually better for powder supplements because its effective serving size is relatively high and consumers already expect creatine powders
The federal Substance Abuse Prevention and Treatment Block Grant and SAMHSA grants support a wide range of services
Journal reference: Jensen, S.B.K., Fiorenza, M., Juhl, C.R